Boehringer Ingelheim awards its first Translational Medicine Award
- The Award recognizes the research that has the highest translational potential
- Translational medicine is an interdisciplinary branch in the biomedical field that aims to combine benchside, bedside and community to promote enhancement in prevention, diagnosis, and treatment
Ingelheim, Germany, October 11, 2021 – Boehringer Ingelheim, a global leader in animal health, has awarded its first biennial Translational Medicine Award during the North American Veterinary Regenerative Medicine Association (NAVRMA 2021) conference in Colorado, US, hosted at the Wayne McIlwraith Translational Medicine Institute at Colorado State University. The Award recognizes the research presentation that has the highest translational potential, identifying six potential award-winning candidates based on evaluation criteria looking at abstract and title and selecting one winner based upon the presentation and responding to the questions.
The general theme of the conference was “collaboration” and with this award Boehringer Ingelheim aims to demonstrate the support and recognition the Company gives to new ideas, passion, and determination to bring a next wave of innovation into the animal health space.
The winning research receives 5,000 USD and a bronze horse for the research that has the highest translational potential; the investigator is awarded with 1,000 USD and the research laboratory 4,000 USD to continue the great work.
This year, Prof. Boaz Arzi from University of California, Davis, has won the Company’s first Translational Medicine Award. His presentation focused on the benefits of treating cats with chronic gingivostomatitis with cellular regenerative therapies.
“We are very excited about the innovative efforts of those who have submitted their research for the Award,” shared Jan Spaas, General Manager Boehringer Ingelheim Veterinary Medicine Belgium. “The presentations were scored based on their innovative character and their ability to become game changers in the veterinary regenerative field. Besides clinical safety and efficacy, the research was judged based on product potency and the development stage into a final product. Other important aspects in the assessment were market potential and the ability to bring value to animal patients.”
The judging panel included the following professors and scientists: Tracy Webb and Wayne McIlwraith from the Colorado State University and Sylvester Price and Jan Spaas from Boehringer Ingelheim.
Congratulations to the winner!
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.
Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.
Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4.1 billion euros in 2020 and presence in more than 150 countries. For more information visit www.boehringer-ingelheim.com/animal-health
Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com
